EPRS Indicates Poor Prognosis and NCP26 Induces Multiple Myeloma Cytotoxicity

Glutamyl-prolyl-tRNA synthetase (EPRS) is an aminoacyl-tRNA synthetase (aaRS) that plays a role in carcinogenesis, but its role in multiple myeloma (MM) is unknown. EPRS is thought to be a growth and survival factor in MM cells, and its expression in patients with MM is correlated with worse outcomes.

Kurata and colleagues developed NCP26, a novel ATP competitive and Pro non-competitive PRS inhibitor, which decreased growth in MM cell lines. Additionally, NCP26 inhibited tumor growth and prolonged survival in mouse models and reduced MM in single-cell RNA-seq in bone marrow samples from patients with MM.